172@29@16@139!~!172@29@0@53!~!|commonstore|commonfiles|moneycontrol_header.php?cid=0&s_cid=0&radar_off=0&is_revamped_header=0&is_responsive=1&sec=PNC_COMPINFO&priceinter=1&frommc=1!~!www|moneycontrol|com!~!|commonstore|commonfiles|moneycontrol_header.php!~!is_mobile=false
Moneycontrol
SENSEX NIFTY
you are here:

Fulford (India) Ltd.

BSE: 506803 | NSE: FULFORD | Series: NA | ISIN: INE521A01017 | SECTOR: Pharmaceuticals

BSE Live

Jul 30, 16:00
2362.00 0.00 (0.00%)
Volume
No Data Available
3,296
  • Prev. Close

    2362.00

  • Open Price

    2350.00

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

Fulford (India) is not traded on BSE in the last 30 days

NSE Live

Dec 27, 11:22
105.00 -1.90 (-1.78%)
Volume
No Data Available
92,389
  • Prev. Close

    106.90

  • Open Price

    -

  • Bid Price (Qty.)

    - (0)

  • Offer Price (Qty.)

    - (0)

Fulford (India) is not listed on NSE
Company History - Fulford (India)
YEAR                                                       EVENTS
 1948 - The Company was incorporated on 2nd March, under the name
 C.E.
        Fulford (India), Ltd., as a wholly owned subsidiary of C.E.
        Fulford, Ltd., U.K.  The company manufacture ethical
        pharmaceutical products which include various speciality
 products
        in the areas of antibiotics, antifungals, antiallergics,
        dermatologicals and corticosteroids.
 
 1968 - The Company was engaged in the business of manufacturing and
        marketing pharmaceutical consumer products which included
 cough
        tablets and herbal ointment marketed under the trade marks
 PEPS
        and ZAM'BUK respectively.
 
      - The Company became a wholly owned subsidiary of Schering
        Corporation U.S.A., which is 100% subsidiary of
 Schering-Plough
        Corporation, U.S.A.
 
 1971 - The Company introduced its first ethical pharmaceutical
 product
        GARAMYCIN.  With the assistance of Schering Corporation,
 U.S.A.
        the Company undertook the manufacture of a range of other
 ethical
        pharmaceutical products.
 
 1980 - In December, Schering-Plough Investments, Ltd., a wholly
 owned
        subsidiary of Schering Corporation U.S.A., acquired the
 entire
        share capital of Schering-Plough Holdings, Ltd.  Thus, this
        company became a direct subsidiary of Schering-Plough
 Holdings,
        Ltd. U.K.
 
      - The Company has entered into an agreement dated 22nd January,
        with C.E. Fulford Ltd., U.K. (now known as Shering-Plough
        Holdings Ltd., U.K.) which grants to the Company a licence to
        continue to use the words C.E. Fulford: or Fulford as part of
        the Company's corporate name.
 
      - 1,000 Pref. and 1,000 Defd. shares converted into 20,000 No.
 of
        Equity shares of Rs 10 each 1,10,000 bonus shares then issued
 in
        prop. 11:5 on 15.2.1980.
 
 1981 - The name of the company was changed to Fulford (India) Pvt.
 Ltd.,
        effective from 9th March.  The Company was converted into a
        public limited company on 12th August, 1981.
 
 1982 - 2,40,000 shares issued at par of which the following shares
 were
        reserved for allotment.  80,000 shares each to ICICI and UTI
 and
        10,000 shares to employees/directors of the Company.  70,000
        shares offered to the public in November 1981.
 
 1988 - 4,00,000 bonus shares issued in proportion 1:1.
 
 1989 - A new dermatological product namely ENSAMYCIN Cream was
        launched during the period.
 
 1991 - The Company focussed its promotional resources on new
 products
        viz., new aminoglycoside (NETROMYCIN) and an anticancer
        (INTRON-A).
 
      - 8,00,000 bonus shares issued in proportion 1:1.
 
 1992 - Another anti-cancer product DROGENIL was launched during the
        year.
 
 1994 - Company has launched two new products viz., LEUCOMAX and
        ELOCON during the year.  LEUCOMAX is an anti-cancer drug
        launched jointly with M/s. Sandoz India Ltd. while ELOCON is
 a
        low/medium potency steriod.
 
      - 16,00,000 bonus shares issued in proportion 1:1.
 
 1995 - ELOCON cream was launched by the company.  Company has also
        received duty exemption for its anti-cancer product LEUCOMAX.
 
 1996 - The Company has launched TOP NITRO: & ETHYOL during the year.
 
 1997 - During the year the company launched `Alaspan' syrup, a
 hi-tech
        product for relief of symptoms associated with allergic
 rhinitis
        which was well accepted in the market.  A new brand of
 Interferon
        Alpha-2b viz. `Viraferon', was also launched for Hepatitis
        segment.
 
      - Schering-Plough (India), Ltd. and Wellnex Pharmaceuticals
 Pvt.,
        Ltd. are subsidiaries of the company.
 
      - The company has also declared an increase in dividend from
 Rs.2
        at the end of March 1995 to Rs.2.10 at end of March 1996. 
 Net
        sales of the company increased by Rs.4,8368 crores from Rs.
        92.5211 crores at the end of March 1995 to Rs.97.3579 crores
 at
        the end of March 1996.
 
 1998 - India (FIL), the Indian arm of Schering Plough, US, is
        prominent in the dermatology and antibiotics segment of the
        pharmaceutical industry.  Its products enjoy leadership
 position
        in their respective categories.
 
      - FIL is active in four main therapeutic areas - dermatology,
        anti-histamines, antibiotics and oncology, with the skincare
        segment (dermatology) accounting for around 50 per cent of
 the
        total turnover.
 
      - The company plans to enter the anti-inflammatory category
 which
        is growing between 5-10 per cent per annum.  This segment is
        dominated by companies including Knoll Pharmaceutical,
 Hoechst
        Marion Roussel and Dr. Reddy's Laboratories.
 
      - Other products which the company introduced are a new
        moisturising skin preparation in the dermatology segment and
        Viraferon for the hepatitis segment.
      
      - The company has a strong balance-sheet and a good financial
 track
        record.
 
      - It also manufactures decongestants and steroids in the form
 of
        ointments, creams, injectables, tables and capsule form.
 
      - Fulford have ventured into its parent company's crore areas
        such as anti-allergy, anti-infection and anti-cancer.
 
 1999 - Polarmine, an anti-histamine, dominates its segment in its
 range
        was been further enhanced with introduction of non-sedating
        anti-histamine-Alaspan.
 
      - The Company had to suspend production of certain products
 during
        the second quarter since the material on hand did not meet
 the
        specifications.
 
      - The Company has achieved Y2K compliance for all its internal
        operations in December 1998.
 
      - The Company is dependent upon suppliers of critical materials
 and
        services, and also public utility providers like power,
 telecom,
        etc. Y2K compliance by these agencies is, therefore, critical
 to
        the company's business.
 
 2001 - City-based pharma company Fulford India Ltd. has permanently
 closed
             down its production facility at Andheri.
 
 
 2007
 s
 -Fulford India Ltd has appointed Mr. Ashley Morris as Director.
 
 2009
 
 - Fulford India Ltd has informed that the Board of Directors of the
 Company have appointed Mr. Rodney Unsworth as Additional Director of
 the Company with effect from March 23, 2009.
 
 2010
 
 - Fulford India Ltd has appointed the following persons as Additional
 Directors of the Company w.e.f. February 02, 2010:
 
 1. Mr. Ramesh Subrahmanian
 2. Mr. Christopher McNamara
 3. Ms. Hwee Ping Chua.
 
 - Fulford India Ltd has informed that Mr. Rajesh Marwaha has been
 appointed as Chief Financial Officer (CFO) of the Company with effect
 from February 02, 2010.
 
 
 2011
 
 - The Company has raised Rs. 40.25 crores by issuing 7,00,000 Equity
 Shares of Rs. 10/- each at a premium of Rs. 565/- per share, to its
 promoters Dashtag.
 
 2012
 -Fulford India  have recommended a dividend of Rs. 3.5/- per share on
 equity share of Rs. 10/- each.
 
 2013
 -Fulford India have recommended a dividend of Re. 1/- per share on
 equity share of Rs. 10/- each.
 
 -2014
 -Fulford India have recommended a final dividend of Rs. 2/- per share
 on equity share of Rs. 10/- each.